Zombie Yellow™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Zombie_Yellow_Viability_Dye_050713
One day old C57BL/6 mouse splenocytes were stained with Zombie Yellow™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie Yellow™ staining, are indicated in black.
  • Zombie_Yellow_Viability_Dye_050713
    One day old C57BL/6 mouse splenocytes were stained with Zombie Yellow™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie Yellow™ staining, are indicated in black.
See Zombie Yellow™ spectral data
Cat # Size Price Quantity Check Availability
423103 100 tests $89.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423104 500 tests $335.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Yellow™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Yellow™ is a polar, water soluble dye providing bright yellow fluorescence, making it suitable for multi-color detection.

Technical data sheet

Product Details

Preparation
Zombie Yellow™ Fixable Viability Kit is composed of lyophilized Zombie Yellow™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Yellow™ dye until fully dissolved. 100 tests = 1 vial of Zombie Yellow™ + DMSO, 500 tests = 5 vials of Zombie Yellow™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Yellow™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Violet Laser (405 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Yellow™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Yellow™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Yellow™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Yellow™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Yellow™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Yellow™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Yellow™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Yellow™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Yellow™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Yellow™.

Zombie Yellow™ dye is excited by the violet laser and has a fluorescence emission maximum of 572 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Yellow™ dye has similar emission to Brilliant Violet 570™.

Application References

(PubMed link indicates BioLegend citation)
  1. Talabot-Ayer D, et al. 2015. J Immunol. 194:750. PubMed
  2. Keppel MP, et al. 2015. J Immunol. 194:1954. PubMed
  3. Shade KT, et al. 2015. J Exp Med. 212:457. PubMed
  4. Souza-Fonesca-Guimaraes F, et al. 2015. PNAS. 112:2376. PubMed
  5. Weiser JN, et al. 2015. J Infect Dis. PubMed
Product Citations
  1. Rose JR, et al. 2023. Commun Biol. 6:363. PubMed
  2. Souza-Fonseca-Guimaraes F, et al. 2016. Cell Death Dis. 7:e2302. PubMed
  3. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  4. Makaryan V, et al. 2022. J Cell Immunol. 4:19. PubMed
  5. Larue MM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2119168119. PubMed
  6. Telzrow CL, et al. 2022. Infect Immun. 90:e0058021. PubMed
  7. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  8. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  9. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  10. Zhou T, et al. 2020. Nature. 583:609. PubMed
  11. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  12. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  13. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  14. Allegrezza M, et al. 2016. Cancer Res . 76: 6253 - 6265. PubMed
  15. Weiser J, et al. 2015. J Infect Dis. 212: 1677 - 1682. PubMed
  16. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  17. Murayama G,et al. 2017. Arthritis Res Ther.. 10.1186/s13075-017-1441-7. PubMed
  18. Park SY, et al. 2022. NPJ Vaccines. 7:123. PubMed
  19. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  20. Souza-Fonseca-Guimaraes F, et al. 2015. Proc Natl Acad Sci U S A. 112:2376. PubMed
  21. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  22. Peterson L, et al. 2016. J Immunol. 197: 4110 - 4117. PubMed
  23. Philip N, et al. 2016. PLoS Pathog. 12:e1005910. PubMed
  24. Renshaw H, et al. 2016. Infect Immun . 84: 1556 - 1564. PubMed
  25. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  26. El–Achkar GA, et al. 2019. PLoS One. 14:e0216405. PubMed
  27. Alturki NA, et al. 2018. Cell Death Dis. 9:592. PubMed
  28. Mathivet T, et al. 2017. EMBO Mol Med.. 10.15252/emmm.201607445. PubMed
  29. Booty MG, et al. 2022. J Immunol. 208:929. PubMed
  30. Stephenson E, et al. 2021. Nat Med. 27:904. PubMed
  31. Rodriguez-Garcia M, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.72. PubMed
  32. Fisher J, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.03.002. PubMed
  33. Hoppstädter J, et al. 2019. Front Immunol. 10:1634. PubMed
  34. Haines RR, et al. 2018. J Immunol. 201:2799. PubMed
  35. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  36. Perales-Puchalt A, et al. 2017. Clin Cancer Res. 23(2):441-453. PubMed
  37. Fallet B, et al. 2020. Cell Rep. 30:1013. PubMed
  38. Hole CR, et al. 2019. Nat Commun. 10:2955. PubMed
  39. Talabot-Ayer D, et al. 2015. J Immunol. 194:750. PubMed
  40. Keppel M, et al. 2015. J Immunol. 194:1954. PubMed
  41. Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed
  42. Lima LG, et al. 2021. Nat Commun. 12:3543. PubMed
  43. Wang JC, et al. 2022. Elife. 11:. PubMed
  44. Zhang S, et al. 2021. Cancer Discov. 0.709722222. PubMed
  45. Putz EJ, et al. 2019. J Dairy Sci. 102:9268. PubMed
  46. Chung NH, et al. 2022. Vaccine. 40:574. PubMed
  47. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  48. Zanvit P, et al. 2015. Nat Commun. 6: 8424. PubMed
  49. Lombardi M, et al. 2016. J Leukoc Biol. 99: 711 - 721. PubMed
  50. Palomo J, et al. 2016. J Immunol. 197: 2239 - 2249. PubMed
  51. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  52. Grubišic V, et al. 2022. Mucosal Immunol. 15:964. PubMed
  53. Islam MR, et al. 2022. Nanotheranostics. 6:451. PubMed
  54. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  55. Keller A, et al. 2017. Nat Immunol. 18:402-411. PubMed
  56. Tanaka Y, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.46. PubMed
  57. Huang N, et al. 2020. Genome Biol. 1.03125. PubMed
  58. Lim J, et al. 2022. J Exp Med. 219:. PubMed
  59. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  60. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
  61. Davidson TB, et al. 2019. Clin Cancer Res. 25:1913. PubMed
  62. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  63. Mittal D, et al. 2016. Cancer Res . 76: 264 - 274. PubMed
  64. Shorter S, et al. 2016. PLoS One. 11: 0149582. PubMed
  65. Spiliopoulou P, et al. 2022. Mol Cancer Ther. . PubMed
  66. Behrens GMN, et al. 2022. Nat Commun. 13:4872. PubMed
  67. Njock MS, et al. 2022. J Extracell Vesicles. 11:e12228. PubMed
  68. Herati RS, et al. 2022. Nat Immunol. 23:1183. PubMed
  69. Binette P, et al. 2022. Front Immunol. 13:894536. PubMed
  70. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  71. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  72. Trial J, et al. 2020. Geroscience. . PubMed
  73. Singh KS, et al. 2021. Nature. 589:597. PubMed
  74. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  75. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  76. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  77. DeFalco T, et al. 2016. Cell Rep. 12: 1107-1119. PubMed
  78. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  79. Tao Z, et al. 2022. Cells. 11:. PubMed
  80. Burel J, et al. 2016. PLoS Pathog. 12: 1005839. PubMed
  81. Haines RR, et al. 2019. J Immunol. 203:1867. PubMed
  82. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  83. Waldman MM, et al. 2022. Front Immunol. 13:856977. PubMed
  84. Teshima T, et al. 2022. Oncol Lett. 24:265. PubMed
  85. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  86. Zheng W, et al. 2019. Cell Rep. 29:1747. PubMed
  87. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA
Go To Top Version: 5    Revision Date: 05/20/2020

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login/Register
Forgot your password? Reset Password
Request an Account